Black Diamond Therapeutics (BDTX) Net Cash Flow (2019 - 2021)
Historic Net Cash Flow for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q4 2021 value amounting to $19.2 million.
- Black Diamond Therapeutics' Net Cash Flow rose 18890.33% to $19.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $31.2 million, marking a year-over-year increase of 12623.7%. This contributed to the annual value of -$19.8 million for FY2024, which is 19177.68% down from last year.
- As of Q4 2021, Black Diamond Therapeutics' Net Cash Flow stood at $19.2 million, which was up 18890.33% from $9.3 million recorded in Q3 2021.
- Over the past 5 years, Black Diamond Therapeutics' Net Cash Flow peaked at $202.5 million during Q1 2020, and registered a low of -$293.2 million during Q2 2020.
- Its 3-year average for Net Cash Flow is $1.3 million, with a median of $2.1 million in 2019.
- Over the last 5 years, Black Diamond Therapeutics' Net Cash Flow had its largest YoY gain of 304025.84% in 2020, and its largest YoY loss of 568545.78% in 2020.
- Black Diamond Therapeutics' Net Cash Flow (Quarter) stood at $76.0 million in 2019, then tumbled by 128.41% to -$21.6 million in 2020, then skyrocketed by 188.9% to $19.2 million in 2021.
- Its last three reported values are $19.2 million in Q4 2021, $9.3 million for Q3 2021, and $23.2 million during Q2 2021.